Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
08/2003
08/14/2003WO2003066077A2 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
08/14/2003WO2003066060A2 Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
08/14/2003WO2003066054A1 Cationic polymers for use in therapeutic agent delivery
08/14/2003WO2003065985A2 Uses of mammalian cytokine; related reagents
08/14/2003WO2003065984A2 Methods and compositions for treating cardiovascular disease
08/14/2003WO2003065973A2 Multivalent streptococcal vaccine compositions and methods for use
08/14/2003WO2003065971A2 Non-myeloablative tolerogenic treatment with tyrphostins
08/14/2003WO2003065881A2 Medical device with coating that promotes endothelial cell adherence and differentiation
08/14/2003WO2003065871A2 Methods and compositions for treating hematological disorders
08/14/2003WO2003065806A1 New immunoeffector compounds
08/14/2003WO2003065787A2 Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
08/14/2003WO2003047617A3 Vaccine
08/14/2003WO2003041652A3 Method of using 18080, a human serine carboxypeptidase family member
08/14/2003WO2003031568A8 Intracellular signaling molecules
08/14/2003WO2003030935A3 Adjuvants for nucleic acid vaccines
08/14/2003WO2003029433A3 Chimeric viral vectors for gene therapy
08/14/2003WO2003022995A3 Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
08/14/2003WO2003020765A3 Vaccine therapies and prophylactic treatments of atherosclerotic diseases
08/14/2003WO2003018768A3 Transmembrane protein differentially expressed in cancer
08/14/2003WO2003017935A3 Human antibodies specific for interleukin 15 (il-15)
08/14/2003WO2003002713A3 Antibodies to opgl
08/14/2003WO2003002069A3 Intradermal delivery of vaccines and gene therapeutic agents via microcannula
08/14/2003WO2002101048A3 NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE
08/14/2003WO2002079241A3 Secreted streptococcus pneumoniae proteins
08/14/2003WO2002076498A3 Bacteriophage-mediated immunisation
08/14/2003WO2002074336A3 Influenza vaccine formulations for intradermal delivery
08/14/2003WO2002059154A9 Neutralizing human monoclonal antibodies against hiv-1, their production and uses
08/14/2003WO2002058626A3 Methods and compositions for the identification and treatment of neurodegenerative disorders
08/14/2003WO2002057453A3 Polypetides and nucleic acids encoding same
08/14/2003WO2002055560A3 Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
08/14/2003WO2002051438A3 Use of repulsive guidance molecule (rgm) and its modulators
08/14/2003WO2002047718A3 Methods and compositions for vaccination comprising nucleic acid ad/or polypeptide sequences of $i(chlamydia)
08/14/2003WO2002029055A3 Carbohydrate-associated proteins
08/14/2003WO2002024145A9 Antiviral substances from plant cuticular and epicuticular material
08/14/2003WO2001090421A3 Method of detecting inflammatory lung disorders
08/14/2003US20030153733 Antibiotic resistant drug screening; vaccines
08/14/2003US20030153532 Immunomodulatory compounds and methods of use thereof
08/14/2003US20030153525 Identifies differential expression of 1465, 1587, 2146, 2207, 32838, 336 OR 52908 genes in tissues relating to pain sensation relative to their expression in normal or non-painful disease states
08/14/2003US20030153524 Including extracellular matrix production and/or deposition, neovascularization, inflammation, cell proliferation, cell migration, associated with connective tissue growth factor by administering agent that decreases expression of the factor
08/14/2003US20030153518 Activation and inhibition of the immune system
08/14/2003US20030153516 Methods and materials for treating and preventing inflammation of mucosal tissue
08/14/2003US20030153504 Antiinflammatory agents selects from a group of tetrapeptides, hexapeptides, octapeptides, oligopeptides, polypeptides
08/14/2003US20030153492 Novel glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
08/14/2003US20030153044 Tissues or organs for use in xenotransplantation
08/14/2003US20030153043 Method for the production of non-immunogenic proteins
08/14/2003US20030153016 PSCA: prostate stem cell antigen
08/14/2003US20030153015 Compositions and methods for the treatment of immune related diseases
08/14/2003US20030153000 Genetic engineering; culture product; recovering
08/14/2003US20030152970 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
08/14/2003US20030152940 Vectors comprise avian lysozyme leader peptide for targetting the endoplasmic reticulum; heparin affinity chromatography
08/14/2003US20030152935 Comprises hybridization probes; electrophoresis; drug screening
08/14/2003US20030152646 Central nervous system disorders; Alzheimer's and Parkinson'sdisease; administering tumor necrosis factor antagonist
08/14/2003US20030152592 Genetic engineering hybrid protein
08/14/2003US20030152590 Virion protein; induce immunology response; genetic engineered Dna
08/14/2003US20030152589 Infecting with bacteriophage; inducting immunology response; forming antibodies
08/14/2003US20030152587 Immunomoderators; high molecular weight polysaccharides
08/14/2003US20030152584 Abundant extracellular products and methods for their production and use
08/14/2003US20030152583 Dna which codes complex
08/14/2003US20030152582 CTL epitopes from EBV
08/14/2003US20030152579 Controlling biosynthesis of hybrid protein; therapy against Helicobacter infections
08/14/2003US20030152576 Antiinflammatory agents; hepatitis virus; vaccines
08/14/2003US20030152575 Using antiidiotypeic antibodies; anticancer, antitumor antibodies
08/14/2003US20030152574 Modulate nucleic acid gene expression
08/14/2003US20030152571 Anti-alphabeta3 humanized monoclonal antibodies
08/14/2003US20030152555 Enhancing cell-based immunotherapy
08/14/2003US20030152514 Methods for using anti-MUC18 antibodies
08/14/2003CA2485064A1 Albumin-fused kunitz domain peptides
08/14/2003CA2483630A1 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations
08/14/2003CA2475539A1 Hiv inhibiting proteins
08/14/2003CA2475446A1 Viral variants with altered susceptibility to nucleoside analogs and uses thereof
08/14/2003CA2475382A1 Albumin-fused anti-angiogenesis peptides
08/14/2003CA2475329A1 Truncated aggrecanase molecules
08/14/2003CA2475326A1 A continuous cell line for the production of vaccines
08/14/2003CA2475066A1 Rhamnose binding protein
08/14/2003CA2475055A1 Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
08/14/2003CA2474800A1 Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications
08/14/2003CA2474728A1 Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
08/14/2003CA2474709A1 Immunostimulatory, covalently lipidated oligonucleotides
08/14/2003CA2474398A1 New immunoeffector compounds
08/14/2003CA2474283A1 Amino acid sequences capable of facilitating penetration across a biological barrier
08/14/2003CA2474011A1 Use of the mammalian cytokine, tslp/il-50, for modulating dendritic cell activity and treatment of immune disorders
08/14/2003CA2473499A1 Minrs as modifiers of insulin receptor signaling and methods of use
08/14/2003CA2472265A1 Immunogenic formulations of variable peptidic epitopes and process for preparation thereof
08/14/2003CA2471207A1 Method of inhibiting pathogenicity of infectious agents
08/14/2003CA2464527A1 Multivalent streptococcal vaccine compositions and methods for use
08/14/2003CA2450807A1 Non-myeloablative tolerogenic treatment with tyrphostins
08/13/2003EP1335023A2 Methods and reagents for vaccination which generate a CD8 T cell immune response
08/13/2003EP1334984A1 Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
08/13/2003EP1334983A2 Inhibitory, monoclonal antibody against the protease which activates clotting factor VII
08/13/2003EP1334730A2 Platelet-specific chimeric immunoglobulin and methods of use therefor
08/13/2003EP1334727A2 Method for obtaining antigenic structures enhancing specific cross reactivity
08/13/2003EP1334201A2 Dna expression vectors
08/13/2003EP1334194A2 Imaging, diagnosis and treatment of disease
08/13/2003EP1334188A2 Cd19-specific redirected immune cells
08/13/2003EP1334187A2 C. elegans genes involved in viability and/or reproduction and uses thereof
08/13/2003EP1334174A2 Paramyxovirus vector for gene transfer to the cardiovascular system
08/13/2003EP1334131A1 Monoclonal antibodies to the map protein and method of use in treating or preventing infections
08/13/2003EP1334126A1 Human stra6-like protein and nucleic acids encoding the same
08/13/2003EP1334119A2 Compositions and methods for modulating rsv infection and immunity
08/13/2003EP1333861A2 Using heat shock proteins to increase immune response
1 ... 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 ... 1823